Literature DB >> 10722524

In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates.

D Milatovic1, F J Schmitz, S Brisse, J Verhoef, A C Fluit.   

Abstract

The in vitro activities of sitafloxacin, ciprofloxacin, trovafloxacin, levofloxacin, clinafloxacin, gatifloxacin, and moxifloxacin against 5,046 gram-negative bacteria, 3,344 gram-positive cocci, and 406 anaerobes were determined. Sitafloxacin was the most active agent against gram-positive cocci and anaerobes. Against Enterobacteriaceae and nonfermenters, its activity was either equivalent to or better than that of clinafloxacin.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10722524      PMCID： PMC89825          DOI： 10.1128/AAC.44.4.1102-1107.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.

Authors:  M Nakashima; T Uematsu; K Kosuge; K Umemura; H Hakusui; M Tanaka
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

2.  In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

3.  In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.

Authors:  C E Nord
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

4.  In vitro susceptibility of anaerobes to quinolones in the United States.

Authors:  D W Hecht; H M Wexler
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

5.  Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.

Authors:  R N Jones; D M Johnson; D J Biedenbach; S A Marshall
Journal:  Diagn Microbiol Infect Dis       Date:  1995-11       Impact factor: 2.803

6.  MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  In vitro activity of DU-6859a against anaerobic bacteria.

Authors:  H M Wexler; E Molitoris; D Reeves; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

8.  In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.

Authors:  T Nakane; S Iyobe; K Sato; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

9.  Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).

Authors:  M G Cormican; S A Marshall; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  1995-01       Impact factor: 2.803

10.  In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone.

Authors:  S A Marshall; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191
View more
  26 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

3.  In vivo efficacies and pharmacokinetics of DX-619, a novel des-fluoro(6) quinolone, against Streptococcus pneumoniae in a mouse lung infection model.

Authors:  Yuichi Fukuda; Katsunori Yanagihara; Hideaki Ohno; Yasuhito Higashiyama; Yoshitsugu Miyazaki; Kazuhiro Tsukamoto; Yoichi Hirakata; Kazunori Tomono; Yohei Mizuta; Takayoshi Tashiro; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.

Authors:  Yasuhiro Kawai; Yukiko Nakura; Tetsu Wakimoto; Makoto Nomiyama; Tsugumichi Tokuda; Toshimitsu Takayanagi; Jun Shiraishi; Kenshi Wasada; Hiroyuki Kitajima; Tomio Fujita; Masahiro Nakayama; Nobuaki Mitsuda; Isao Nakanishi; Makoto Takeuchi; Itaru Yanagihara
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

6.  Pharmacodynamics of moxifloxacin against anaerobes studied in an in vitro pharmacokinetic model.

Authors:  Alan R Noel; Karen E Bowker; Alasdair P Macgowan
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

8.  Factor analysis of microbiological activity data and structural parameters of antibacterial quinolones.

Authors:  Marcin Koba; Tomasz Baczek; Katarzyna Macur; Leszek Bober; Teresa Frackowiak; Adam Buciński; Danuta Rystok-Grabska; Jolanta Stasiak; Katarzyna Koba
Journal:  J Mol Model       Date:  2009-07-15       Impact factor: 1.810

Review 9.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.